Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The therapeutic efficacy of the new compound N-benzo[B]-furan-2-ylcarbonyl-N'-benzylpiperazine hydrochloride (befuraline) was evaluated in 64 patients presenting various depressive syndromes. Improvement was found in 33 cases (= 52%) under a daily dose of 150 mg befuraline; 31 of these patients improved within the first 8 days of treatment. Patients with endogenous depression responded favourably to the befuraline therapy, 23 (= 70%) of these (33) patients showing full recovery. Improvement was more frequently observed in patients with mild depression than in severe cases. It seems noteworthy that under befuraline treatment there was also a marked improvement in 21 cases in whom previous long-term therapy with other psychotropic drugs had remained ineffective. Side effects consisted mainly of reversible psycho-organic troubles; extrapyramidal disorders were not observed.
 ...
PMID:[Open study of befuraline (DIV 154) in 64 depressive patients (author's transl)]. 34 6

Francis William Reitz, the second last President of the Republic of the Orange Free State, resigned his office on 16 November 1895 for health reasons. He died 39 years later at the age of 89. An analysis of this health history shows his resignation to have been caused by a symptom complex quite characteristic of endogenous depression, probably precipitated by virus hepatitis, During 1896 he recovered fully, but in 1903, as an embittered man at the end of the Anglo-Boer War, he experienced a severe recurrence of depression which lasted 18 months, despite the best therapy available in Europe at the time.
 ...
PMID:[President F.W. Reitz and his health problem]. 36 80

The author describes a controlled, double-blind, comparative trial of a new tetracyclic compound, ciclazindol (WY 23409), against amitriptyline in the treatment of thirty-five patients admitted to hospital with depressive illness. Each patient was randomly allocated to three weeks treatment with either 50 mg b.d. ciclazindol or 50 mg b.d. amitriptyline. In the event of a poor response the dose level was raised to 75 mg b.d. Separation of cases of endogenous depression and severity of depression were assessed by the Levine-Pilowsky Depression Questionnaire, a self-rating technique. Severity of depression was also assessed using the Hamilton Rating Scale. No significant difference was noted between the drugs in either the degree or the rate of response nor when the endogenous cases alone were studied. The interesting observation was made that only one-third of ciclazindol patients gained weight compared to almost three-quarters of the amitriptyline group and the mean weight gain of the latter was over double that of the ciclazindol group. The author concludes that ciclazindol offers promise and merits further study using higher dosage levels once its full safety trials have been completed.
 ...
PMID:A controlled comparative trial of a new antidepressant, ciclazindol. 36 21

Fifty patients with moderate to severe primary depression were treated in equal groups of inpatients and outpatients with a constant dose of 60 mg. of mianserin daily for four weeks in a double blind placebo controlled trial with either a three times daily dosage regime or a single nightly dose. There was no difference in apparent compliance, side effects or therapeutic effect in either day-time or night-time dosage regimes. Patients developing high plasma levels of mianserin (greater than 70 microgram/l) were associated with a highly significantly poorer therapeutic outcome. Patients identified as endogenous depression demonstrated a significant negative correlation between plasma levels of mianserin and therapeutic response measured as an amelioration of either the Hamilton Rating Scale scores (r = --0.48) or on a new depression scale by Montgomery and Asberg (r = --0.51) with high levels associated with poor response. There was a significant correlation (r = 0.66) between mianserin plasma levels and age in endogenous depression. In those patients identified as suffering from reactive depression, no significant relationship could be seen between plasma levels and therapeutic response or with age. These findings support the view that the relationship between mianserin plasma levels and clinical response is more likely to be demonstrated in endogenous depression.
 ...
PMID:Mianserin plasma levels and differential clinical response in endogenous and reactive depression. 37 84

20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and steady-state concentration were very good (r = 0.81, 0.97, 0.94; p less than 0.0001) and better than the correlation between half-life and steady-state (r = 0.65; p less than 0.01). The Spearman rank correlations (Rs) between amelioration of depression measured by the Hamilton Rating Scale (HRS) and the 24, 48 and 72 hour concentrations were highly significant (Rs = 0.74, 0.79, 0.79; p less than 0.001) but for half-life (Rs = 0.33) the correlation was not significant. The single 48 hour plasma nortriptyline concentration following a single oral dose is recommended as a reliable simplified monitoring test suitable for a busy clinic. The test is useful for dosage adjustment to maximise antidepressant action and minimise toxicity. A tentative dosage adjustment schedule for individualising antidepressant treatment with nortriptyline based on the 48 hour or the 24 hour plasma concentration is proposed.
 ...
PMID:Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients. 37

A double-blind controlled, cross-over trial was carried out in 70 depressed patients to compare the effectiveness and tolerability of amineptine with that of maprotiline. Patients were allocated at random to receive treatment with either 150 mg amineptine or 75 mg maprotiline daily for 6 weeks before being treated for a further 6 weeks with the alternative drug. Comparison of the response to treatment at the end of each period showed that amineptine was significantly better than maprotiline, and this was particularly marked in the 46 patients with exogenous depression where an effect was usually evident within 3 to 5 days. Only 6 patients in this group failed to show a response to amineptine compared with 19 to maprotiline. Both drugs appeared to be equally effective overall in patients with endogenous depression, although when amineptine was given as the second treatment there was an improvement in retardation. Few side-effects were reported during either treatment period.
 ...
PMID:Cross-over trial comparing the antidepressant effects of amineptine and maprotiline. 38 Sep 10

The effectiveness of trazodone was assessed over a 4-week period under double-blind conditions. Twenty-eight inpatients with a diagnosis of endogenous depression received either trazodone, imipramine, or placebo. Trazodone was significantly better than placebo and frequently better than imipramine according to analyses of the results of the Hamilton Psychiatric Scale for Depression, severity of illness and clinical global improvement ratings, and the Global Ward Behavior Scale. Significant improvement was evident in the trazodone group by the end of the first week of therapy, particularly in those symptoms associated with depression and accompanying anxiety. There were fewer side effects with trazodone than with imipramine.
 ...
PMID:Trazodone, a new antidepressant: efficacy and safety in endogenous depression. 38 4

A double-blind controlled trial comparing the antidepressant activity of amitriptyline with lofepramine is reported. Forty-six patients entered the 4-week trial. Analysis of the Hamilton Depression Rating Scale scores at the beginning and end of the trial showed no significant difference between the therapeutic efficacy of lofepramine and amitriptyline. However, patients with endogenous depression responded significantly more rapidly to lofepramine as measured by Visual Analogue Scales and showed a significantly greater degree of clinical improvement after 4 weeks' treatment, as measured by Global Assessment. Adverse effects were similar in the two treatment groups. The use of rating scales in trials of depressive illnesses is discussed. The Visual Analogue Scale for depression was found to be a simple, useful and valid measure.
 ...
PMID:The comparative antidepressant value of lofepramine and amitriptyline. Results of a controlled trial with comments on the scales used. 38 88

A double-blind trial was undertaken to compare the antidepressant efficacy and the side effects of Lofepramine with those of Amitriptyline in the treatment of endogenous depression. The study involves 22 acutely ill endogenously depressive patients. 11 patients were treated with Lofepramine and the remaining 11 with Amitriptyline. The results demonstrate that both substances are effective in the treatment of depression. However, the therapeutical efficacy of Lofepramine is significantly greater than that of Amitriptyline. Furthermore, the tolerance of Lofepramine is better than that of Amitriptyline, and the side effects of Amitriptyline, especially in blood pressure dysregulation, are greater than those of Lofepramine.
 ...
PMID:A double-blind trial with amitriptyline and lofepramine in the treatment of endogenous depression. 39 29

In a double-blind study among six patients suffering from endogenous depression, three patients received thyrotropin-Releasing Hormone (TRH) administered orally in doses of 20 mg three times a day for 3 weeks. In an open controlled study of three patients suffering from endogenous depression, two patients received oral TRH 20 mg four times a day for 2 weeks. Degree of depression according to Hamilton's Rating Scale measured during the study showed that TRH had no antidepressant effect. Thyroxine concentration in serum (T4) increased during the period of TRH treatment.
 ...
PMID:Treatment of endogenous depressions with thyrotropin-releasing hormone (TRH) under oral administration. 40 95


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>